Treating 26-month-old mice (roughly equivalent to 75-year-old humans) with lamivudine
for as little as two weeks reduced evidence of both the interferon response and inflammation, while treating 20-month-old mice with lamivudine
for six months also reduced signs of fat and muscle loss as well as kidney scarring.
This meta-analysis affirms the effectiveness of lamivudine
in the prevention of vertical transmission of HBV infection.
was obtained from GlaxoSmithKline (Suzhou, China).
Patients who were HBeAg(-) in the lamivudine
and entecavir groups prior to treatment were also HBeAg(-) in their final follow-up assessments.
Samples positive for both HBsAg and HBV DNA were HBV genotyped by phylogenetic methods, and the HBV polymerase gene was sequenced to detect mutations known to be associated with lamivudine
resistance (rtV173L, rtV180M, rtA181T/V, rtT184G and rtM204V/I) using Bioedit software (http//:www.mbio.ncsu.edu/bioedit).
Though only 13 patients were under Tenofovir, Lamivudine
and Efavirenz regimen, abnormalities in LFT, Lipid Profile and Serum Ca 2+ and PO4 levels were seen in more proportions in TLE regimen compared to 185 patients with Tenofovir, Lamivudine
and Nevirapine regimen.
is a nucleoside analog reverse transcription inhibitor of HIV and hepatitis B virus that acts as a synthetic cytidine analog.
Among the patients who were given treatment, lamivudine
(4 mg/kg/day) was given to 29 patients (80.5%), IFN-[alpha] (6 MU/[m.sup.2], three days a week) was given to 3 (8.3%) patients and both IFN-[alpha] and lamivudine
(complementary treatment) was given to 4 patients (11.2%).
Preliminary data indicate that the development of multiple lamivudine
associated mutations may even reduce the efficacy of tenofovir therapy .
The investigators enrolled 280 patients who carried virus with lamivudine-resistant mutations, were viremic (HBV DNA greater than [10.sup.3]/IU per mL), and were still on lamivudine
until the day of random ization.
This step is mainly targeted by nucleos(t)ide analogues such as lamivudine
, adefovir, entecavir, tenofovir, and telbivudine.
The four drugs (atazanavir, ritonavir, tenofovir and lamivudine
) will be sold as three pills, with tenofovir and lamivudine
combined into a single pill, at US$475 a year.
(Epivir[R], GlaxoSmithKline) was first approved by the FDA for the treatment of human immunodeficiency virus (HIV) infection at a dose of 150 mg twice a day or 300 mg once a day.
Generics manufacturer Cipla Medpro, which said its new 300 mg dosage was as effective as the currently available twice-daily dose of lamivudine
, was also the first to launch Triomune, a 3-in-1 ARV, in South Africa in 2006.
Telbivudine, an L-nucleoside that showed "potent and specific anti-HBV activity" in preliminary studies, was found safe and effective when compared with lamivudine
in an international phase III clinical trial, researchers reported in the New England Journal of Medicine.